Contact Information <\/p>\n
Available for logged-in reporters only <\/p>\n
Newswise Up to 30 percent of heart attack patients suffer a new heart attack because cardiologists are unable to control inflammation inside heart arteries the process that leads to clots rupturing and causing myocardial infarction or stroke. <\/p>\n
But a report in Nature Communications by Icahn School of Medicine at Mount Sinai scientists showcases the development of a new technology that may provide a solution to this high risk of repeat heart attacks and potentially help save more lives. <\/p>\n
An international research team, led by Mount Sinai investigators, designed and tested a high-density lipoprotein (HDL) nanoparticle loaded with a statin drug. In mouse studies, they show this HDL nanotherapy is capable of directly targeting and lowering dangerous inflammation in blood vessels. <\/p>\n
Not only could the HDL nanotherapy potentially avert repeat heart attacks, it may also have the power to reduce recurrent strokes caused by clots in brain arteries, says the studys senior investigator, Willem Mulder, PhD, Associate Professor of Radiology in the Translational and Molecular Imaging Institute at the Icahn School of Medicine at Mount Sinai. <\/p>\n
We envision that a safe and effective HDL nanotherapy could substantially lower cardiovascular events during the critical period of vulnerability after a heart attack or stroke, says Dr. Mulder. <\/p>\n
While we have much more to do to confirm clinical benefit in patients, our study shows how this nanotherapy functions biologically, and how this novel concept could potentially also work in the clinical setting to solve a critical problem, says Dr. Mulder. This nanotherapy would be the first of its kind. <\/p>\n
Inject HDL Statin Nanotherapy Right After Heart Attack and Stroke Treatment The research team, led by two PhD graduate students as first authors Raphael Duivenvoorden, MD, and Jun Tang, MS fashioned the nanoparticle to resemble an HDL cholesterol particle. In fact, the nanoparticle binds on to the same receptors as natural HDL in order to deliver the statin drug. <\/p>\n
Oral statin medications used by millions of people today work primarily in the liver to reduce levels of unhealthy lipids, such as low density lipoproteins (LDL), that circulate in the blood. Statins also exert a very weak dampening effect on some inflammatory cells, foremost those called macrophages that hide within plaque in the arterial walls. <\/p>\n
<\/p>\n
View original post here: <\/p>\n
Novel Nanotherapy Breakthrough May Help Reduce Recurrent Heart Attacks and Stroke<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Contact Information Available for logged-in reporters only Newswise Up to 30 percent of heart attack patients suffer a new heart attack because cardiologists are unable to control inflammation inside heart arteries the process that leads to clots rupturing and causing myocardial infarction or stroke. But a report in Nature Communications by Icahn School of Medicine at Mount Sinai scientists showcases the development of a new technology that may provide a solution to this high risk of repeat heart attacks and potentially help save more lives Continue reading